Jazz Pharmaceuticals Income Statement (2010-2025) | JAZZ

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Mar2021	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025
Revenue & cost
Revenue (Quarter)	607.58M	751.81M	838.12M	896.73M	813.72M	932.88M	940.65M	972.12M	892.81M	957.32M	972.14M	1,011.93M	901.98M	1,023.83M	1,054.97M	1,088.17M		1,045.71M	1,126.11M	1,197.93M
Cost of Revenue (Quarter)	40.19M	119.19M	145.22M	136.15M	115.28M	124.21M	133.66M	167.36M	128.64M	97.54M	102.15M	107.24M	95.49M	109.90M	111.61M	128.71M		116.27M	128.88M	153.53M
Gross Profit (Quarter)	567.39M	632.62M	692.89M	760.58M	698.44M	808.67M	806.99M	804.76M	764.17M	859.78M	869.99M	904.69M	806.50M	913.92M	943.36M	959.46M		929.44M	997.23M	1,044.40M
Operating items
Amortization - Intangibles (Quarter)	68.19M	140.48M	159.80M	157.29M	172.09M	148.46M	141.23M	137.39M	149.79M	152.06M	154.88M	151.55M	155.73M	155.22M	157.46M	158.90M		162.10M	168.37M	169.74M
Research & Development (Quarter)	76.57M	132.70M	141.04M	155.44M	129.98M	139.05M	148.87M	172.56M	189.41M	209.24M	234.40M	216.61M	222.85M	220.73M	199.92M	240.50M		189.97M	198.20M	213.91M
Selling, General & Administrative (Quarter)	260.51M	429.03M	363.68M	398.46M	308.81M	366.47M	358.48M	383.20M	297.92M	340.84M	308.31M	396.03M	351.71M	338.52M	325.77M	369.29M		358.40M	530.65M	406.21M
Restructuring Costs (Quarter)
Other Operating Expenses (Quarter)	108.38M	259.67M	305.03M	293.45M	287.38M	341.81M	408.54M	679.75M	279.43M	249.60M	257.04M	276.80M	261.22M	265.12M	269.07M	287.62M		1,183.73M	339.75M	323.27M
Operating Expenses (Quarter)	445.46M	821.40M	809.75M	847.35M	726.17M	847.33M	915.89M	1,235.51M	766.76M	799.68M	799.75M	889.44M	835.78M	824.38M	794.76M	897.40M		1,732.10M	1,068.60M	943.39M
Operating Income (Quarter)	162.12M	-69.59M	28.37M	49.38M	87.55M	85.55M	24.76M	-263.39M	126.06M	157.64M	172.39M	122.50M	66.21M	199.44M	260.21M	190.77M		-686.39M	57.51M	254.53M
EBIT (Quarter)	162.12M	-69.59M	28.37M	49.38M	87.55M	85.55M	24.76M	-263.39M	126.06M	157.64M	172.39M	122.50M	66.21M	199.44M	260.21M	190.77M		-686.39M	57.51M	254.53M
Non-operating items
Interest & Investment Income (Quarter)	-27.38M	-69.42M	-93.37M	-88.60M	-70.68M	-63.19M	-80.24M	-74.12M	-74.15M	-73.47M	-71.50M	-70.32M	-66.12M	-62.02M	-58.70M	-51.26M		-47.36M	-48.58M	-45.41M
Other Non Operating Income (Quarter)	0.94M	2.95M	-2.63M	-5.61M	-10.54M	-1.34M	-4.65M	-2.48M	3.19M	-2.38M	-1.38M	9.35M	-1.69M	0.51M	-0.70M	-6.29M		-1.80M	0.10M	-0.66M
Non Operating Income (Quarter)
Net income details
EBT (Quarter)	135.69M	-136.06M	-67.63M	-44.83M	6.33M	21.01M	-60.13M	-339.99M	55.10M	81.78M	99.52M	61.53M	-1.60M	137.93M	200.81M	133.22M		-735.55M	9.04M	208.47M
Tax Provisions (Quarter)	18.02M	228.60M	-18.06M	-12.48M	0.50M	-16.10M	-43.00M	-100.00M	-15.30M	-24.32M	-47.18M	-33.08M	11.70M	-30.65M	-14.50M	-57.88M		-17.17M	-242.42M	5.01M
Profit After Tax (Quarter)	121.83M	-363.32M	-52.83M	-35.35M	1.65M	34.66M	-19.65M	-240.72M	69.42M	104.44M	146.82M	94.15M	-14.62M	168.57M	215.06M	191.12M	-92.54M	-718.47M	251.41M	203.45M
Equity Income (Quarter)	4.17M	1.36M	-3.26M	-2.99M	-4.14M	-2.46M	-2.54M	-0.77M	-1.00M	-1.67M	0.13M	-0.46M	-1.35M	-0.01M	-0.28M	-0.02M		-0.09M	-0.05M	-0.06M
Income from Non-Controlling Interests (Quarter)
Income from Continuing Operations (Quarter)	117.67M	-364.66M	-49.58M	-32.35M	5.83M	37.11M	-17.13M	-239.99M	70.40M	106.11M	146.69M	94.60M	-13.30M	168.58M	215.31M	191.10M		-718.38M	251.46M	203.47M
Consolidated Net Income (Quarter)	117.67M	-364.66M	-49.58M	-32.35M	5.83M	37.11M	-17.13M	-239.99M	70.40M	106.11M	146.69M	94.60M	-13.30M	168.58M	215.31M	191.10M		-718.38M	251.46M	203.47M
Income towards Parent Company (Quarter)	117.67M	-364.66M	-49.58M	-32.35M	5.83M	37.11M	-17.13M	-239.99M	70.40M	106.11M	146.69M	94.60M	-13.30M	168.58M	215.31M	191.10M		-718.38M	251.46M	203.47M
Net Income towards Common Stockholders (Quarter)	117.67M	-364.66M	-49.58M	-32.35M	5.83M	37.11M	-17.13M	-239.99M	70.40M	106.11M	146.69M	94.60M	-13.30M	168.58M	215.31M	191.10M		-718.38M	251.46M	203.47M
Additional items
EPS (Basic) (Quarter)	2.16	-6.11	-0.86	-0.54	0.03	0.56	-0.31	-3.85	1.09	1.63	2.33	1.50	-0.23	2.68	3.50	3.13		-11.74	4.14	3.34
EPS (Weighted Average and Diluted) (Quarter)	2.09	-6.11	-0.86	-0.54	0.03	0.55	-0.31	-3.84	1.04	1.52	2.14	1.43	-0.23	2.49	3.42	3.02		-11.74	4.08	3.34
Shares Outstanding (Weighted Average) (Quarter)	56.47M	57.97M	61.28M	59.69M	61.87M	62.44M	62.37M	62.54M	63.49M	63.99M	63.53M	63.29M	62.54M	62.71M	61.41M	61.84M	60.98M	61.09M	60.70M	60.98M
Shares Outstanding (Diluted Average) (Quarter)	58.39M	57.97M	61.28M	59.69M	62.91M	63.43M	63.39M	62.54M	73.77M	73.66M	71.29M	72.07M	62.54M	69.68M	67.51M	66.01M		61.09M	61.61M	60.98M
EBITDA (Quarter)	162.12M	-69.59M	28.37M	49.38M	87.55M	85.55M	24.76M	-263.39M	126.06M	157.64M	172.39M	122.50M	-54.87M	199.44M	260.21M	190.77M	69.52M	-686.39M	57.51M	254.53M
Interest Expenses (Quarter)
Tax Rate (Quarter)	13.28%	-168.01%	26.70%	27.85%	7.91%	-76.62%	71.51%	29.41%	-27.77%	-29.74%	-47.40%	-53.76%	-730.34%	-22.22%	-7.22%	-43.45%		2.33%	-2,683.17%	2.40%

Research Tools

Jazz Pharmaceuticals Income Statement (2010-2025) | JAZZ

Create an account

Sign In

Reset Password